O Orexo AB
O
Cerrado
14.86 -1.46
Resumen
Variación precio
24h
Mínimo
14.56
Máximo
15.96
Ingresos | -28M -103M |
|---|---|
Ventas | -1.5M 3.5M |
BPA | -2.535 |
Margen de beneficios | -2,951.429 |
Empleados | 61 |
EBITDA | -21M -95M |
Próximas Ganancias | 22 oct 2026 |
|---|
Capitalización Mercado | -236M 579M |
|---|---|
Apertura anterior | 16.32 |
Cierre anterior | 14.86 |
Orexo AB Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Orexo AB previsión
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.